Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.31 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28474927 | 1.00 | UHRF1 (0.32) | UHRF1ADRA2AADRA2BADRA2CNPC1 | |
| Hydrochloric Acid SCHEMBL30092129 | 1.00 | UHRF1 (0.32) | UHRF1ADRA2AADRA2BADRA2CNPC1 | |
| Hydrochloric Acid SCHEMBL3031125 | 1.00 | UHRF1 (0.32) | UHRF1ADRA2AADRA2BADRA2CNPC1 | |
| Hydrochloric Acid SCHEMBL30092204 | 1.00 | UHRF1 (0.32) | UHRF1ADRA2AADRA2BADRA2CNPC1 | |
| Hydrochloric Acid SCHEMBL20644229 | 1.00 | UHRF1 (0.32) | UHRF1ADRA2AADRA2BADRA2CNPC1 | |
| SCHEMBL29613118 | 0.98 | UHRF1 (0.33) | UHRF1NPC1LMNAMAPTRAB9A | |
| SCHEMBL2339196 | 0.98 | UHRF1 (0.33) | UHRF1NPC1LMNAMAPTRAB9A | |
| SCHEMBL8053862 | 0.98 | UHRF1 (0.33) | UHRF1NPC1LMNAMAPTRAB9A | |
| SCHEMBL1763628 | 0.81 | UHRF1 (0.34) | UHRF1 | |
| SCHEMBL179362 | 0.78 | NPC1 (0.36) | UHRF1NPC1LMNAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053411-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-23 | — | — | US | disclosed |
| CN-110256418-B | 1, 3-thiazol-2-yl substituted benzamides | 拜耳公司 | 2023-01-20 | — | — | CN | disclosed |
| EP-3587417-B9 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AG (DE) | 2022-03-30 | — | — | EP | disclosed |
| EP-3587417-B1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AG (DE) | 2022-01-05 | — | — | EP | disclosed |
| US-11142523-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-12 | — | — | US | disclosed |
| EP-3230281-B1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AG (DE) | 2021-05-26 | — | — | EP | disclosed |
| CN-107207507-B | 1, 3-thiazol-2-yl substituted benzamides | 拜耳公司 | 2020-11-06 | — | — | CN | disclosed |
| US-20200131169-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-30 | — | — | US | disclosed |
| US-10472354-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2019-11-12 | — | — | US | disclosed |
| US-20190185466-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-06-20 | — | — | US | disclosed |
| US-10202369-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-12 | — | — | US | disclosed |
| US-10183937-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2019-01-22 | — | — | US | disclosed |
| US-10174016-B2 | 1,3-thiazol-2-yl substituted benzamides | BEYER AKTIENGESELLSCHAFT (DE) | 2019-01-08 | — | — | US | disclosed |
| US-20180118731-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | US | disclosed |
| US-20180093980-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180072713-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-03-15 | — | — | US | disclosed |
| EP-3230281-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | Bayer Aktiengesellschaft (DE) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016091776-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093980-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | ADRA2A 1185/4885ADRA2B 1725/4885ADRA2C 1010/4885 |
| US-20230053411-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | ADRA2A 1185/4885ADRA2B 1725/4885ADRA2C 1010/4885 |
| US-20180118731-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | ADRA2A 1185/4885ADRA2B 1725/4885ADRA2C 1010/4885 |
| US-20190185466-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | ADRA2A 1185/4885ADRA2B 1725/4885ADRA2C 1010/4885 |
| US-10202369-B2 | 1,3-thiazol-2-yl substituted benzamides | NAT1, HNMT, PMP22 | ADRA2A 1185/4885ADRA2B 1725/4885ADRA2C 1010/4885 |
| US-10472354-B2 | 1,3-thiazol-2-yl substituted benzamides | NAT1, HNMT, PMP22 | ADRA2A 1185/4885ADRA2B 1725/4885ADRA2C 1010/4885 |
| US-10174016-B2 | 1,3-thiazol-2-yl substituted benzamides | NAT1, HNMT, PMP22 | ADRA2A 1185/4885ADRA2B 1725/4885ADRA2C 1010/4885 |
| US-10183937-B2 | 1,3-thiazol-2-yl substituted benzamides | NAT1, HNMT, PMP22 | ADRA2A 1185/4885ADRA2B 1725/4885ADRA2C 1010/4885 |
| US-11142523-B2 | 1,3-thiazol-2-yl substituted benzamides | NAT1, HNMT, PMP22 | ADRA2A 1185/4885ADRA2B 1725/4885ADRA2C 1010/4885 |
| US-20180072713-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | ADRA2A 1185/4885ADRA2B 1725/4885ADRA2C 1010/4885 |
| US-20200131169-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | ADRA2A 1185/4885ADRA2B 1725/4885ADRA2C 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.